Changfeng Pharmaceuticals completed a 630 million yuan round of E financing for the development of respiratory drugs

Changfeng Pharmaceutical Co., Ltd. (CF PharmTech, Inc., referred to as "Longwind Pharmaceuticals") recently successfully completed the E round of financing, this round of financing led by United New Capital, China Resources Zhengda Life Fund (CR-CP Life), Source Venture Capital, Junxin Capital, Keystone Capital, Xiangcheng Gold Control, Longma peak investment and other institutions to participate. At the same time, Yuanyu Holdings, Suzhou Longmen Venture Capital Fund, Gautejia and China Merchants International Capital and other old shareholders continue to increase their holdings. Yikai Capital serves as an exclusive financial advisor in the current round of financing transactions in Changfeng.Prior to this, Changfeng Pharmaceuticals has completed five rounds of financing, Kaifeng Ventures, Yuanyu Origin, Jinpu Investment, Longmen Investment, Yuanming Capital, China Investment Innovation, CCB International and other well-known investment institutions have participated in the investment.Changfeng Pharmaceuticals is a comprehensive pharmaceutical company dedicated to providing high-quality respiratory drugs to patients worldwide. Since its inception, it has focused on the development of therapeutic drugs for respiratory diseases worldwide and has established an advanced research and development base for inhalation preparations and production facilities for the global high-end market. At this stage, Changfeng Pharmaceuticals for China, the United States, Europe and other domestic and foreign markets declared more than 20 research projects, including the treatment of respiratory diseases of several heavy drugs. (
arterial
)